Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Daisuke Yabe, Yoshiyuki Hamamoto, Yusuke Seino, Hitoshi Kuwata, Takeshi Kurose & Yutaka Seino. (2017) Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation. Expert Opinion on Drug Safety 16:10, pages 1211-1218.
Read now
Read now
Yukihiro Chino, Masatoshi Hasegawa, Yoshiki Fukasawa, Yoko Mano, Kagumi Bando, Atsunori Miyata, Yasuhiro Nakai, Hiromi Endo & Jun-ichi Yamaguchi. (2017) In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor. Xenobiotica 47:4, pages 314-323.
Read now
Read now
Atsunori Miyata, Masatoshi Hasegawa, Kenji Hachiuma, Haruyuki Mori, Nobuko Horiuchi, Akiko Mizuno-Yasuhira, Yukihiro Chino, Shigeji Jingu, Soichi Sakai, Yoshishige Samukawa, Yasuhiro Nakai & Jun-ichi Yamaguchi. (2017) Metabolite profiling and enzyme reaction phenotyping of luseogliflozin, a sodium–glucose cotransporter 2 inhibitor, in humans. Xenobiotica 47:4, pages 332-345.
Read now
Read now
Articles from other publishers (9)
Dan Nakano, Jun Akiba, Tsubasa Tsutsumi, Machiko Kawaguchi, Takafumi Yoshida, Hironori Koga & Takumi Kawaguchi. (2022) Hepatic expression of sodium–glucose cotransporter 2 (SGLT2) in patients with chronic liver disease. Medical Molecular Morphology 55:4, pages 304-315.
Crossref
Crossref
Anirudh Manoj, Subham Das, Anu Kunnath Ramachandran, Angel T Alex & Alex Joseph. (2020) SGLT2 inhibitors, an accomplished development in field of medicinal chemistry: an extensive review. Future Medicinal Chemistry 12:21, pages 1961-1990.
Crossref
Crossref
Kashif Haider, Ankita Pathak, Ankit Rohilla, Md Rafi Haider, Kamal Ahmad & M. Shahar Yar. (2019) Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review. European Journal of Medicinal Chemistry 184, pages 111773.
Crossref
Crossref
Kohnosuke Kinoshita, Motoki Ochi, Katsuya Iwata, Misako Fukasawa & Jun‐ichi Yamaguchi. (2019) Preclinical disposition of MGS0274 besylate, a prodrug of a potent group II metabotropic glutamate receptor agonist MGS0008 for the treatment of schizophrenia. Pharmacology Research & Perspectives 7:5.
Crossref
Crossref
Shinji Kobuchi, Megumi Matsuno, Momoko Kawamoto, Naoto Kojima, Yukako Ito, Masayuki Yamashita & Toshiyuki Sakaeda. (2017) A simple and rapid LC–MS/MS method for quantitation of luseogliflozin in rat plasma and its application to a PK study. Bioanalysis 9:2, pages 163-171.
Crossref
Crossref
Yoshishige SamukawaMasaru MutohShi ChenNobuo Mizui. (2017) Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling of Luseogliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Japanese Patients with Type 2 Diabetes Mellitus. Biological & Pharmaceutical Bulletin Biological and Pharmaceutical Bulletin 40:8, pages 1207-1218.
Crossref
Crossref
Tushar Madaan, Mohd. Akhtar & Abul Kalam Najmi. (2016) Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective. European Journal of Pharmaceutical Sciences 93, pages 244-252.
Crossref
Crossref
Soichi Sakai, Kohei Kaku, Yutaka Seino, Nobuya Inagaki, Masakazu Haneda, Takashi Sasaki, Atsushi Fukatsu, Haruka Kakiuchi & Yoshishige Samukawa. (2016) Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials. Clinical Therapeutics 38:4, pages 843-862.e9.
Crossref
Crossref
Minoru Sasaki, Takanobu Sakurai, Aiko Ishii, Kenta Matsue, Yutaka Nakanishi, Shunsuke Tsutsumi & Yasushi Sato. (2016) Evaluation of potential activity of luseogliflozin on vascular proliferation in the mesenteric lymph node with or without vascular tumors in Sprague-Dawley rats in a carcinogenicity study. Journal of Toxicologic Pathology 29:2, pages 85-93.
Crossref
Crossref